Published in Cancer Weekly, May 5th, 2009
"Postmenopausal women with advanced breast cancer and >= 1 visceral (liver or lung) lesion were randomized to anastrozole (1 mg/day orally) or exemestane (25 mg/day orally) for >= 8 weeks. The primary endpoint was objective response In visceral lesions based on modified Response Evaluation...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.